Earnings call transcript: Physitrack posts record Q3 2026 revenue as stock rises

Physitrack reported record Q3 revenue of EUR 3.6 million, up 14% year over year and matching the forecast, with 94% of revenue recurring and the core platform growing 26%. Adjusted EBITDA margin declined to 31% from 38% as the company invested in launches; management retained its medium-term 40%–45% margin target and expects EMR subscriptions to begin contributing in January 2027. Nearly 5,000 users across almost 500 clinics signed up for EMR early access, and shares rose 2.48% to $12.40 in premarket trading.

Analysis

The upside case is a workflow-migration story, not an AI-feature story: if EMR adoption embeds Physitrack in scheduling, documentation and billing, it can raise retention and cross-sell RTM and education. But early-access registrations are not a paid pipeline; management’s ARR illustration depends on assumed conversion and pricing. Existing-user uptake may largely deepen wallet share rather than prove broad-market product fit. Established clinic-software vendors and lower-cost AI-native entrants can respond, while integrations, local billing rules and support needs may constrain the promised low-cost rollout.

Near term (days to weeks), the reaction can stay constructive, but the revenue result itself offered no forecast beat. Over 1–3 months, the Nov. 2 wider release and Q4 commercialization are the proof points; monitor paid clinic count, conversion by new versus existing users, and sequential ARR—not registrations. Over 6–18 months, operating leverage is real only if revenue accelerates while costs and CapEx stabilize. Margin recovery to the stated 40–45% target is management’s objective, not yet demonstrated; flat sequential ARR and lower free cash flow make execution the key risk. Customer concentration in Wellness and modest liquidity headroom add downside sensitivity if growth disappoints.

Contrarian take: a mature core product growing well and high recurring mix may be underappreciated, but the market may be over-crediting AI novelty before monetization. No valuation or reliable liquidity data supports chasing PTRK here; the article also contains conflicting share-price references, which should be reconciled before sizing any position. Thesis breaks if paid EMR conversion is weak, ARR remains flat after launch, churn rises, or margins fail to stabilize as costs level off.

Key Decisions for Investors

• PTRK: Do not chase the headline. Keep on a watchlist; consider a small, staged long only after the wider release produces verifiable paid conversions and ARR re-accelerates. Confirm current price, trading liquidity and the share-price discrepancy first.
• Track the next 1–2 reports for EMR paid clinics and ARR, conversion split between existing and new customers, churn, CapEx, and EBITDA margin. Treat registration totals and management’s modeled ARR as leading indicators, not booked revenue.
• Trim or abandon a prospective long if ARR stays flat after paid subscriptions begin, customer churn worsens, or margins continue falling despite the stated cost plateau. Avoid assigning value to the 40–45% margin target until reported results show a recovery.
• Do not infer an investment read-through to Atlassian (TEAM) from its passing mention as a company inspiration, or to Banco Santander (SAN) from the revolving-credit reference; neither is shown to have material earnings exposure here.